XFOR Earnings & Financial Statements
X4 Pharmaceuticals, Inc.
$2.45
-$0.15(-5.77%)
37
Overall
60
Value
18
Tech
34
Quality
Market Cap
$242.91M
Volume
705.74K
52W Range
$2.70 - $4.83
Target Price
$11.60
XFOR earnings and financial statements: X4 Pharmaceuticals, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
XFOR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $35.11M | $2.56M | $195.0K | $196.0K | - |
| Cost of revenue | $5.76M | $797.0K | - | - | - |
| Operating income | -$86.88M | -$36.40M | -$107.52M | -$87.57M | -$85.11M |
| EBITDA | -$69.00M | -$27.58M | -$94.89M | -$89.33M | -$84.54M |
| Net income | -$79.20M | -$37.45M | -$101.17M | -$93.87M | -$88.70M |
| EPS (diluted) | $-1.87 | $-5.70 | $-17.10 | $-45.60 | $-119.70 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $290.46M | $146.45M | $147.26M | $155.59M | $117.18M |
| Total liabilities | $104.17M | $124.30M | $96.16M | $81.53M | $52.76M |
| Shareholders’ equity | $186.29M | $22.15M | $51.10M | $74.05M | $64.41M |
| Cash and equivalents | $217.05M | $55.70M | $99.22M | $121.72M | $81.79M |
| Long-term debt | - | $1.41M | $57.18M | $35.91M | $4.78M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$85.60M | -$130.90M | -$96.51M | -$77.10M | -$70.91M |
| Capital expenditure | - | $104.67M | -$60.0K | -$103.0K | -$615.0K |
| Free cash flow | -$85.60M | -$131.23M | -$96.57M | -$77.20M | -$71.52M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XFOR | $2.45 | -5.8% | 705.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get X4 Pharmaceuticals, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW